281 related articles for article (PubMed ID: 30502220)
1. Clinical Impact of the Polypill for Cardiovascular Prevention in Latin America: A Consensus Statement of the Inter-American Society of Cardiology.
Sosa-Liprandi Á; Sosa Liprandi MI; Alexánderson E; Avezum Á; Lanas F; López-Jaramillo JP; Martínez F; Ponte-Negretti N CI; Wyss F; González Juanatey JR; Perel P
Glob Heart; 2019 Mar; 14(1):3-16.e1. PubMed ID: 30502220
[TBL] [Abstract][Full Text] [Related]
2. Considerations and Guidance for the Structure, Organisation, and Operation of Cardiometabolic Prevention Units: A Consensus Statement of the Inter-American Society of Cardiology.
Ponte-Negretti CI; Wyss FS; Piskorz D; Liprandi ÁS; Lorenzatti A; Machado L; López-Jaramillo P; Barbosa E; Gómez-Mancebo JR; López-Santi R; Valdez O; Cobos L; Puente-Barragan A; Borrayo G; Ruiz E
Glob Heart; 2021 Apr; 16(1):27. PubMed ID: 34040940
[TBL] [Abstract][Full Text] [Related]
3. Influenza Vaccination for the Prevention of Cardiovascular Disease in the Americas: Consensus document of the Inter-American Society of Cardiology and the Word Heart Federation.
Liprandi ÁS; Liprandi MIS; Zaidel EJ; Aisenberg GM; Baranchuk A; Barbosa ECD; Sánchez GB; Alexander B; Zanetti FTL; Santi RL; Múnera-Echeverri AG; Perel P; Piskorz D; Ruiz-Mori CE; Saucedo J; Valdez O; Juanatey JRG; Piñeiro DJ; Pinto FJ; Quintana FSW
Glob Heart; 2021; 16(1):55. PubMed ID: 34381676
[TBL] [Abstract][Full Text] [Related]
4. The cardiovascular polypill: clinical data and ongoing studies.
Castellano JM; Bueno H; Fuster V
Int J Cardiol; 2015 Dec; 201 Suppl 1():S8-14. PubMed ID: 26747391
[TBL] [Abstract][Full Text] [Related]
5. Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome.
López-Jaramillo P; Barbosa E; Molina DI; Sanchez R; Diaz M; Camacho PA; Lanas F; Pasquel M; Accini JL; Ponte-Negretti CI; Alcocer L; Cobos L; Wyss F; Sebba-Barroso W; Coca A; Zanchetti A;
J Hypertens; 2019 Jun; 37(6):1126-1147. PubMed ID: 30882601
[TBL] [Abstract][Full Text] [Related]
6. A polypill strategy to improve adherence: results from the FOCUS project.
Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK.
Becerra V; Gracia A; Desai K; Abogunrin S; Brand S; Chapman R; García Alonso F; Fuster V; Sanz G
BMJ Open; 2015 May; 5(5):e007111. PubMed ID: 25991449
[TBL] [Abstract][Full Text] [Related]
8. Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease.
Wood F; Salam A; Singh K; Day S; Jan S; Prabhakaran D; Rodgers A; Patel A; Thom S; Ward H
BMJ Open; 2015 Sep; 5(9):e008018. PubMed ID: 26423850
[TBL] [Abstract][Full Text] [Related]
9. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality.
Castellano JM; Sanz G; Fernandez Ortiz A; Garrido E; Bansilal S; Fuster V
J Am Coll Cardiol; 2014 Aug; 64(6):613-21. PubMed ID: 25104532
[TBL] [Abstract][Full Text] [Related]
10. Global burden of CVD: focus on secondary prevention of cardiovascular disease.
Bansilal S; Castellano JM; Fuster V
Int J Cardiol; 2015 Dec; 201 Suppl 1():S1-7. PubMed ID: 26747389
[TBL] [Abstract][Full Text] [Related]
11. Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease.
González-Juanatey JR; Mostaza JM; Lobos JM; Abarca B; Llisterri JL; Baron-Esquivias G; Galve E; Lidón RM; Garcia-Moll FX; Sánchez PL; Suárez C; Millán J; Pallares V; Alemán JJ; Egocheaga I
Med Clin (Barc); 2017 Feb; 148(3):139.e1-139.e15. PubMed ID: 27993410
[TBL] [Abstract][Full Text] [Related]
12. Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE).
Ponte-Negretti CI; Wyss FS; Piskorz D; Santos RD; Villar R; Lorenzatti A; López-Jaramillo P; Toth PP; Amaro AJJ; Rodrigo AK; Lanas F; Urina-Triana M; Lara J; Valdés TO; Gomez-Mancebo JR; Bryce A; Cobos S L; Puente-Barragan A; Ullauri-Solórzano VE; Medina-Palomino FA; Lozada AF; Duran M; Berrospi P; Miranda D; Badimon JJ; González JJR; Libby P
Arch Cardiol Mex; 2022 Jan; 92(1):99-112. PubMed ID: 34187049
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
[TBL] [Abstract][Full Text] [Related]
14. The concept of the polypill in the prevention of cardiovascular disease.
Wiley B; Fuster V
Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy in Older Adults with Cardiovascular Disease: Report from an American College of Cardiology, American Geriatrics Society, and National Institute on Aging Workshop.
Schwartz JB; Schmader KE; Hanlon JT; Abernethy DR; Gray S; Dunbar-Jacob J; Holmes HM; Murray MD; Roberts R; Joyner M; Peterson J; Lindeman D; Tai-Seale M; Downey L; Rich MW
J Am Geriatr Soc; 2019 Feb; 67(2):371-380. PubMed ID: 30536694
[TBL] [Abstract][Full Text] [Related]
16. [Adherence to pharmacological treatments: searching for new solutions].
Di Fusco SA; Spinelli A; Di Pasquale G; Aquilani S; Imperoli G; Colivicchi F
G Ital Cardiol (Rome); 2024 Jan; 25(1):15-21. PubMed ID: 38140993
[TBL] [Abstract][Full Text] [Related]
17. The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.
Tamargo J; Castellano JM; Fuster V
Int J Cardiol; 2015 Dec; 201 Suppl 1():S15-22. PubMed ID: 26747390
[TBL] [Abstract][Full Text] [Related]
18. Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review.
Lopez-Lopez JP; Gonzalez AM; Lanza P; Lopez-Jaramillo P
Vasc Health Risk Manag; 2023; 19():605-615. PubMed ID: 37719697
[TBL] [Abstract][Full Text] [Related]
19. Polypill: quo vadis?
Muscente F; De Caterina R
J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):783-92. PubMed ID: 27341194
[TBL] [Abstract][Full Text] [Related]
20. The value of the polypill in cardiovascular disease: an Italian multidisciplinary Delphi panel consensus.
Perrone-Filardi P; Minghetti P; Menditto E; Bianchi S; Scaglione F; Trifirò G; Piccinocchi G; Corona T; Gambarelli G; Izzi C; Misciagna V; Putignano D; Lopatriello S; Cafiero D
J Cardiovasc Med (Hagerstown); 2021 Apr; 22(4):246-258. PubMed ID: 33633039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
